CD40 and cancer: To evaluate whether there might be a predictive value of CD40 for immunotherapy, we utilized the Tumor Immune Dysfunction and Exclusion (TIDE) framework (tide.dfci.harvard.edu), which is a computational framework developed to evaluate potential of tumor immune escape based on the gene expression profiles of cancer samples.